Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk. (November 2011)

• Record Type: Journal Article
• Authors: Nicholls, Stephen J; Uno, Kiyoko; Kataoka, Yu
• Is Part Of: Expert review of cardiovascular therapy. Volume 9:Number 11(2011)
• Page Start: 1383
• Page End: 1390
• Publication Date: 2011-11
• Subjects: atherosclerosis -- cardiovascular disease -- clinical trials -- lipids -- risk factors -- rosuvastatin; Cardiovascular agents -- Research -- Periodicals; 616.12061
• DOI: 10.1586/erc.11.145
• Languages: English
• ISSNs: 1477-9072

Abstract

On the basis of large randomized clinical trials, pharmacological antagonists of HMG-CoA reductase (statins) have become increasingly used in clinical practice for the prevention of cardiovascular disease. Rosuvastatin was developed as a potent statin, which appeared to raise levels of HDL-cholesterol, in addition to marked reductions in levels of LDL-cholesterol. These effects on lipids are associated with a beneficial impact of rosuvastatin on progression of various stages of atherosclerosis and cardiovascular outcomes in clinical trials. The clinical experience of rosuvastatin will be reviewed in this article.